Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 90 | 2025 | 456 | 31.490 |
Why?
|
Myocardial Infarction | 88 | 2024 | 1015 | 16.190 |
Why?
|
Platelet Aggregation Inhibitors | 76 | 2025 | 440 | 14.890 |
Why?
|
Rivaroxaban | 27 | 2024 | 253 | 9.530 |
Why?
|
Aspirin | 32 | 2024 | 376 | 7.770 |
Why?
|
Stroke | 41 | 2024 | 1063 | 7.050 |
Why?
|
Acute Coronary Syndrome | 34 | 2024 | 267 | 6.560 |
Why?
|
Lactones | 24 | 2022 | 58 | 6.320 |
Why?
|
Purinergic P2Y Receptor Antagonists | 27 | 2025 | 66 | 6.160 |
Why?
|
Lower Extremity | 26 | 2025 | 402 | 5.990 |
Why?
|
Thrombosis | 21 | 2024 | 324 | 5.930 |
Why?
|
Secondary Prevention | 42 | 2024 | 219 | 5.740 |
Why?
|
Adenosine | 20 | 2023 | 211 | 5.660 |
Why?
|
Pyridines | 27 | 2022 | 475 | 5.660 |
Why?
|
Fibrinolytic Agents | 16 | 2024 | 246 | 5.410 |
Why?
|
Vascular Surgical Procedures | 14 | 2024 | 293 | 5.180 |
Why?
|
Atherosclerosis | 22 | 2025 | 403 | 5.070 |
Why?
|
Factor Xa Inhibitors | 16 | 2024 | 169 | 5.060 |
Why?
|
Ischemia | 26 | 2024 | 395 | 4.850 |
Why?
|
Endovascular Procedures | 12 | 2024 | 302 | 4.490 |
Why?
|
Hemorrhage | 44 | 2025 | 645 | 4.390 |
Why?
|
Coronary Artery Disease | 17 | 2025 | 678 | 4.000 |
Why?
|
Treatment Outcome | 96 | 2025 | 10152 | 3.710 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2024 | 413 | 3.680 |
Why?
|
Diabetes Mellitus, Type 2 | 25 | 2025 | 2430 | 3.520 |
Why?
|
Cardiovascular Diseases | 29 | 2024 | 1999 | 3.100 |
Why?
|
Venous Thromboembolism | 13 | 2025 | 271 | 3.070 |
Why?
|
Troponin I | 10 | 2022 | 75 | 3.010 |
Why?
|
Humans | 267 | 2025 | 128418 | 2.900 |
Why?
|
Drug Therapy, Combination | 28 | 2025 | 1009 | 2.900 |
Why?
|
Aged | 127 | 2025 | 21953 | 2.880 |
Why?
|
Anticholesteremic Agents | 7 | 2024 | 146 | 2.770 |
Why?
|
Risk Factors | 76 | 2025 | 9704 | 2.690 |
Why?
|
Aortic Diseases | 5 | 2022 | 114 | 2.660 |
Why?
|
Brain Ischemia | 8 | 2022 | 305 | 2.610 |
Why?
|
Double-Blind Method | 45 | 2025 | 1848 | 2.440 |
Why?
|
Anticoagulants | 18 | 2025 | 613 | 2.390 |
Why?
|
Thrombolytic Therapy | 8 | 2021 | 130 | 2.370 |
Why?
|
Middle Aged | 113 | 2025 | 30889 | 2.320 |
Why?
|
Drug-Eluting Stents | 4 | 2023 | 64 | 2.120 |
Why?
|
Risk Assessment | 33 | 2025 | 3232 | 2.030 |
Why?
|
Heart Failure | 17 | 2024 | 2145 | 2.000 |
Why?
|
Male | 141 | 2025 | 62858 | 2.000 |
Why?
|
Diabetes Mellitus | 11 | 2023 | 1000 | 1.970 |
Why?
|
Randomized Controlled Trials as Topic | 23 | 2025 | 1356 | 1.940 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2022 | 561 | 1.920 |
Why?
|
Dyslipidemias | 4 | 2021 | 176 | 1.920 |
Why?
|
Cholesterol, LDL | 7 | 2024 | 360 | 1.900 |
Why?
|
Female | 139 | 2025 | 68154 | 1.890 |
Why?
|
Atrial Fibrillation | 6 | 2025 | 377 | 1.820 |
Why?
|
Receptor, PAR-1 | 10 | 2019 | 21 | 1.780 |
Why?
|
Walking | 7 | 2025 | 494 | 1.770 |
Why?
|
Intermittent Claudication | 7 | 2025 | 118 | 1.670 |
Why?
|
Glucosides | 8 | 2020 | 38 | 1.640 |
Why?
|
Benzhydryl Compounds | 8 | 2020 | 66 | 1.600 |
Why?
|
ST Elevation Myocardial Infarction | 6 | 2025 | 52 | 1.580 |
Why?
|
Ventricular Function, Left | 4 | 2024 | 524 | 1.560 |
Why?
|
Hospitalization | 12 | 2025 | 2057 | 1.470 |
Why?
|
Blood Coagulation Disorders | 2 | 2023 | 162 | 1.400 |
Why?
|
Percutaneous Coronary Intervention | 8 | 2025 | 466 | 1.330 |
Why?
|
Embolism | 2 | 2022 | 41 | 1.320 |
Why?
|
Stroke Volume | 6 | 2024 | 586 | 1.310 |
Why?
|
Time Factors | 35 | 2025 | 6482 | 1.310 |
Why?
|
Troponin T | 6 | 2022 | 57 | 1.270 |
Why?
|
Hypolipidemic Agents | 2 | 2021 | 93 | 1.260 |
Why?
|
Extremities | 6 | 2021 | 128 | 1.210 |
Why?
|
Coronary Thrombosis | 4 | 2018 | 23 | 1.200 |
Why?
|
Follow-Up Studies | 27 | 2022 | 4892 | 1.190 |
Why?
|
Hypoglycemic Agents | 11 | 2025 | 1212 | 1.090 |
Why?
|
Postoperative Complications | 3 | 2024 | 2485 | 1.080 |
Why?
|
Piperazines | 8 | 2014 | 336 | 1.080 |
Why?
|
Glucagon-Like Peptides | 2 | 2025 | 49 | 1.080 |
Why?
|
Receptors, Thrombin | 5 | 2015 | 12 | 1.070 |
Why?
|
Biomarkers | 29 | 2025 | 3880 | 1.050 |
Why?
|
Vascular Diseases | 4 | 2023 | 232 | 1.020 |
Why?
|
Phosphatidylcholine-Sterol O-Acyltransferase | 2 | 2022 | 5 | 1.010 |
Why?
|
Kaplan-Meier Estimate | 16 | 2024 | 853 | 1.010 |
Why?
|
Electrocardiography | 8 | 2018 | 604 | 1.000 |
Why?
|
Sterol O-Acyltransferase | 2 | 2022 | 5 | 1.000 |
Why?
|
Cardiovascular Agents | 4 | 2022 | 152 | 0.980 |
Why?
|
Myocardial Ischemia | 6 | 2021 | 248 | 0.960 |
Why?
|
Hypercholesterolemia | 2 | 2024 | 101 | 0.950 |
Why?
|
Mobile Applications | 2 | 2024 | 159 | 0.940 |
Why?
|
Incretins | 1 | 2025 | 18 | 0.940 |
Why?
|
Kidney Diseases | 5 | 2020 | 367 | 0.920 |
Why?
|
Prasugrel Hydrochloride | 6 | 2024 | 22 | 0.920 |
Why?
|
Incidence | 16 | 2025 | 2616 | 0.910 |
Why?
|
Limb Salvage | 6 | 2024 | 58 | 0.900 |
Why?
|
International Classification of Diseases | 1 | 2024 | 123 | 0.880 |
Why?
|
Chest Pain | 4 | 2017 | 89 | 0.870 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2023 | 78 | 0.860 |
Why?
|
Cardiology | 3 | 2022 | 260 | 0.860 |
Why?
|
Acute Disease | 8 | 2021 | 964 | 0.850 |
Why?
|
Acetanilides | 6 | 2014 | 11 | 0.840 |
Why?
|
Recurrence | 21 | 2024 | 996 | 0.830 |
Why?
|
Patient Selection | 3 | 2022 | 663 | 0.820 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 2 | 0.810 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 47 | 0.810 |
Why?
|
Prospective Studies | 22 | 2025 | 7036 | 0.810 |
Why?
|
Outpatients | 3 | 2024 | 366 | 0.780 |
Why?
|
Disease Management | 3 | 2025 | 587 | 0.770 |
Why?
|
Medicare | 9 | 2024 | 715 | 0.750 |
Why?
|
Paclitaxel | 2 | 2021 | 214 | 0.740 |
Why?
|
Serine Proteinase Inhibitors | 2 | 2020 | 43 | 0.740 |
Why?
|
Databases, Factual | 5 | 2024 | 1269 | 0.730 |
Why?
|
Cerebrovascular Disorders | 2 | 2018 | 89 | 0.720 |
Why?
|
Proprotein Convertase 9 | 6 | 2021 | 68 | 0.720 |
Why?
|
Beneficence | 1 | 2021 | 17 | 0.720 |
Why?
|
Dyspnea | 2 | 2020 | 238 | 0.710 |
Why?
|
Platelet Aggregation | 5 | 2023 | 91 | 0.710 |
Why?
|
Myocarditis | 2 | 2019 | 98 | 0.710 |
Why?
|
Research Subjects | 1 | 2021 | 42 | 0.700 |
Why?
|
Personal Autonomy | 1 | 2021 | 48 | 0.690 |
Why?
|
Diabetes Complications | 2 | 2021 | 223 | 0.680 |
Why?
|
Prognosis | 15 | 2024 | 3772 | 0.680 |
Why?
|
Renal Insufficiency | 2 | 2021 | 148 | 0.680 |
Why?
|
Sex Characteristics | 2 | 2023 | 721 | 0.670 |
Why?
|
Cholesterol | 4 | 2022 | 406 | 0.670 |
Why?
|
Caffeine | 1 | 2020 | 61 | 0.670 |
Why?
|
Beverages | 1 | 2020 | 67 | 0.670 |
Why?
|
Lipoproteins, HDL | 4 | 2024 | 85 | 0.660 |
Why?
|
Informed Consent | 1 | 2021 | 168 | 0.650 |
Why?
|
Leg | 1 | 2021 | 240 | 0.640 |
Why?
|
Patient Care Team | 1 | 2024 | 605 | 0.630 |
Why?
|
United States | 22 | 2025 | 13830 | 0.620 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2020 | 127 | 0.620 |
Why?
|
Ezetimibe | 1 | 2018 | 26 | 0.620 |
Why?
|
Syndrome | 5 | 2023 | 335 | 0.620 |
Why?
|
Quality of Life | 4 | 2025 | 2680 | 0.610 |
Why?
|
Stents | 4 | 2021 | 503 | 0.610 |
Why?
|
Consensus | 2 | 2022 | 613 | 0.600 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2023 | 99 | 0.590 |
Why?
|
Aged, 80 and over | 15 | 2024 | 7033 | 0.590 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 488 | 0.580 |
Why?
|
Blood Platelets | 5 | 2023 | 376 | 0.580 |
Why?
|
Drug Administration Schedule | 10 | 2024 | 751 | 0.580 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 330 | 0.570 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2021 | 1936 | 0.570 |
Why?
|
Hypertension | 3 | 2025 | 1235 | 0.570 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 39 | 0.550 |
Why?
|
Neoplasms | 3 | 2023 | 2464 | 0.550 |
Why?
|
Proportional Hazards Models | 11 | 2021 | 1196 | 0.550 |
Why?
|
Cause of Death | 8 | 2024 | 393 | 0.540 |
Why?
|
Medical Oncology | 1 | 2019 | 271 | 0.540 |
Why?
|
Survival Rate | 6 | 2021 | 1869 | 0.540 |
Why?
|
Heparin | 3 | 2023 | 240 | 0.530 |
Why?
|
Smoking Cessation | 2 | 2024 | 408 | 0.530 |
Why?
|
Enzyme Inhibitors | 5 | 2014 | 809 | 0.500 |
Why?
|
Death, Sudden, Cardiac | 3 | 2018 | 179 | 0.500 |
Why?
|
Patient Readmission | 1 | 2021 | 664 | 0.500 |
Why?
|
Ulcer | 2 | 2021 | 29 | 0.490 |
Why?
|
Hematoma | 2 | 2021 | 54 | 0.480 |
Why?
|
Ankle Brachial Index | 5 | 2025 | 36 | 0.470 |
Why?
|
Blood Glucose | 1 | 2025 | 2093 | 0.470 |
Why?
|
Non-ST Elevated Myocardial Infarction | 3 | 2019 | 19 | 0.470 |
Why?
|
Benzazepines | 3 | 2019 | 40 | 0.460 |
Why?
|
Apolipoprotein A-I | 2 | 2024 | 28 | 0.450 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 1355 | 0.450 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2025 | 112 | 0.440 |
Why?
|
Thiophenes | 2 | 2011 | 118 | 0.440 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 34 | 0.440 |
Why?
|
Global Health | 4 | 2021 | 327 | 0.430 |
Why?
|
Ranolazine | 7 | 2014 | 25 | 0.410 |
Why?
|
Venous Thrombosis | 3 | 2025 | 161 | 0.400 |
Why?
|
Life Style | 1 | 2015 | 460 | 0.400 |
Why?
|
Lecithins | 2 | 2022 | 4 | 0.400 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 14 | 0.400 |
Why?
|
Intracranial Hemorrhages | 5 | 2018 | 78 | 0.400 |
Why?
|
MicroRNAs | 3 | 2023 | 677 | 0.390 |
Why?
|
Cohort Studies | 10 | 2022 | 5388 | 0.380 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 2523 | 0.380 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2023 | 173 | 0.380 |
Why?
|
Multicenter Studies as Topic | 5 | 2021 | 285 | 0.380 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2012 | 143 | 0.370 |
Why?
|
Enoxaparin | 2 | 2021 | 59 | 0.360 |
Why?
|
Antibodies, Monoclonal, Humanized | 4 | 2021 | 755 | 0.350 |
Why?
|
Thrombin | 3 | 2021 | 142 | 0.350 |
Why?
|
Angina Pectoris | 2 | 2009 | 67 | 0.340 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2009 | 138 | 0.330 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2021 | 90 | 0.330 |
Why?
|
Exercise Tolerance | 2 | 2025 | 268 | 0.320 |
Why?
|
Appetite Depressants | 2 | 2019 | 16 | 0.310 |
Why?
|
Thromboembolism | 3 | 2024 | 102 | 0.300 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 993 | 0.300 |
Why?
|
Retrospective Studies | 9 | 2024 | 14454 | 0.300 |
Why?
|
Coronary Artery Bypass | 3 | 2016 | 221 | 0.300 |
Why?
|
Exercise | 2 | 2021 | 1929 | 0.300 |
Why?
|
Troponin | 3 | 2020 | 50 | 0.290 |
Why?
|
Hospital Mortality | 3 | 2021 | 844 | 0.290 |
Why?
|
Adult | 21 | 2025 | 35300 | 0.290 |
Why?
|
Europe | 3 | 2021 | 359 | 0.290 |
Why?
|
Risk | 5 | 2019 | 853 | 0.290 |
Why?
|
Registries | 7 | 2025 | 1877 | 0.280 |
Why?
|
Ticlopidine | 5 | 2016 | 54 | 0.280 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 2 | 2018 | 45 | 0.280 |
Why?
|
Factor XI | 2 | 2024 | 9 | 0.280 |
Why?
|
American Heart Association | 3 | 2022 | 298 | 0.280 |
Why?
|
Metabolic Syndrome | 2 | 2021 | 338 | 0.280 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2019 | 175 | 0.270 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 1204 | 0.270 |
Why?
|
Ventricular Function | 1 | 2006 | 60 | 0.260 |
Why?
|
Glomerular Filtration Rate | 3 | 2019 | 681 | 0.260 |
Why?
|
Popliteal Artery | 2 | 2023 | 58 | 0.260 |
Why?
|
Internationality | 3 | 2022 | 148 | 0.260 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2023 | 28 | 0.240 |
Why?
|
Angioplasty, Balloon | 3 | 2023 | 88 | 0.240 |
Why?
|
Diabetic Nephropathies | 2 | 2019 | 278 | 0.240 |
Why?
|
Obesity | 4 | 2019 | 2858 | 0.240 |
Why?
|
Peptide Fragments | 2 | 2023 | 684 | 0.240 |
Why?
|
Pulmonary Embolism | 2 | 2025 | 202 | 0.240 |
Why?
|
Heterocyclic Compounds, 2-Ring | 1 | 2024 | 8 | 0.230 |
Why?
|
Pravastatin | 2 | 2016 | 26 | 0.230 |
Why?
|
Recovery of Function | 3 | 2025 | 641 | 0.230 |
Why?
|
Injections, Subcutaneous | 1 | 2025 | 144 | 0.230 |
Why?
|
Walk Test | 1 | 2025 | 69 | 0.230 |
Why?
|
Aortic Aneurysm | 2 | 2016 | 64 | 0.230 |
Why?
|
Immunotherapy | 2 | 2019 | 587 | 0.230 |
Why?
|
Angiography | 2 | 2024 | 192 | 0.230 |
Why?
|
Comorbidity | 3 | 2020 | 1543 | 0.230 |
Why?
|
Severity of Illness Index | 3 | 2018 | 2722 | 0.220 |
Why?
|
Cardiovascular System | 2 | 2022 | 137 | 0.220 |
Why?
|
Pragmatic Clinical Trials as Topic | 2 | 2021 | 62 | 0.220 |
Why?
|
Heptanoic Acids | 2 | 2015 | 62 | 0.220 |
Why?
|
Angioplasty | 1 | 2023 | 47 | 0.210 |
Why?
|
Age Factors | 5 | 2024 | 3103 | 0.210 |
Why?
|
Psychiatric Rehabilitation | 1 | 2023 | 3 | 0.210 |
Why?
|
Angina, Unstable | 3 | 2013 | 77 | 0.210 |
Why?
|
Arteries | 2 | 2022 | 262 | 0.210 |
Why?
|
Thromboplastin | 1 | 2023 | 69 | 0.210 |
Why?
|
Computed Tomography Angiography | 1 | 2024 | 115 | 0.210 |
Why?
|
Echocardiography | 2 | 2024 | 623 | 0.210 |
Why?
|
Pyrroles | 2 | 2015 | 191 | 0.200 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 1815 | 0.200 |
Why?
|
Pyridones | 1 | 2024 | 159 | 0.200 |
Why?
|
Kidney | 2 | 2020 | 1302 | 0.200 |
Why?
|
Liraglutide | 1 | 2022 | 29 | 0.190 |
Why?
|
Thiazoles | 1 | 2022 | 115 | 0.190 |
Why?
|
Coronary Angiography | 1 | 2024 | 306 | 0.190 |
Why?
|
Symporters | 1 | 2022 | 54 | 0.190 |
Why?
|
Numbers Needed To Treat | 1 | 2021 | 7 | 0.190 |
Why?
|
Doxorubicin | 1 | 2023 | 322 | 0.190 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 1935 | 0.190 |
Why?
|
Inflammation | 3 | 2023 | 2654 | 0.190 |
Why?
|
Mobility Limitation | 1 | 2022 | 61 | 0.190 |
Why?
|
Warfarin | 1 | 2022 | 146 | 0.190 |
Why?
|
Frailty | 1 | 2024 | 153 | 0.190 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 15 | 0.180 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 215 | 0.180 |
Why?
|
Antihypertensive Agents | 1 | 2025 | 485 | 0.180 |
Why?
|
Myocardial Revascularization | 4 | 2021 | 69 | 0.180 |
Why?
|
Precision Medicine | 1 | 2025 | 384 | 0.180 |
Why?
|
Pyrimidines | 1 | 2024 | 445 | 0.180 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2023 | 198 | 0.180 |
Why?
|
Tissue Plasminogen Activator | 1 | 2022 | 219 | 0.180 |
Why?
|
Placebos | 1 | 2021 | 201 | 0.170 |
Why?
|
Drug Therapy | 1 | 2021 | 77 | 0.170 |
Why?
|
Heart Diseases | 2 | 2016 | 345 | 0.170 |
Why?
|
Exercise Therapy | 3 | 2022 | 413 | 0.170 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2021 | 185 | 0.170 |
Why?
|
Methylamines | 1 | 2020 | 27 | 0.170 |
Why?
|
Blood Coagulation | 1 | 2021 | 227 | 0.170 |
Why?
|
Survival Analysis | 2 | 2014 | 1263 | 0.170 |
Why?
|
Medication Adherence | 1 | 2024 | 560 | 0.170 |
Why?
|
Carcinoma, Renal Cell | 1 | 2022 | 179 | 0.170 |
Why?
|
Reproducibility of Results | 4 | 2023 | 3020 | 0.160 |
Why?
|
Glucagon-Like Peptide Receptors | 1 | 2019 | 1 | 0.160 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 40 | 0.160 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 168 | 0.160 |
Why?
|
Lipoprotein(a) | 1 | 2020 | 67 | 0.160 |
Why?
|
Patient Education as Topic | 1 | 2024 | 737 | 0.160 |
Why?
|
Sleep Apnea Syndromes | 1 | 2020 | 79 | 0.160 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 64 | 0.160 |
Why?
|
Heart | 1 | 2023 | 635 | 0.160 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 1 | 2019 | 6 | 0.160 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 71 | 0.160 |
Why?
|
Weight Loss | 3 | 2019 | 725 | 0.160 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2009 | 21 | 0.160 |
Why?
|
Microcirculation | 1 | 2019 | 137 | 0.160 |
Why?
|
Hemoglobins | 1 | 2021 | 336 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 26 | 0.160 |
Why?
|
Pharmacovigilance | 1 | 2018 | 21 | 0.160 |
Why?
|
Cardiac Rehabilitation | 1 | 2019 | 35 | 0.160 |
Why?
|
Adamantane | 1 | 2018 | 15 | 0.150 |
Why?
|
Drug Approval | 2 | 2019 | 86 | 0.150 |
Why?
|
Coronary Disease | 2 | 2018 | 382 | 0.150 |
Why?
|
Platelet Activation | 2 | 2017 | 88 | 0.150 |
Why?
|
Dipeptides | 1 | 2018 | 48 | 0.150 |
Why?
|
Reoperation | 1 | 2021 | 557 | 0.150 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 596 | 0.150 |
Why?
|
Canagliflozin | 1 | 2018 | 9 | 0.150 |
Why?
|
Young Adult | 6 | 2024 | 12312 | 0.150 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2018 | 74 | 0.150 |
Why?
|
Research Personnel | 1 | 2020 | 156 | 0.150 |
Why?
|
Ischemic Attack, Transient | 2 | 2015 | 60 | 0.150 |
Why?
|
Anti-Obesity Agents | 1 | 2018 | 53 | 0.150 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 349 | 0.140 |
Why?
|
Calibration | 1 | 2018 | 135 | 0.140 |
Why?
|
Peripheral Vascular Diseases | 1 | 2018 | 102 | 0.140 |
Why?
|
Health Care Costs | 1 | 2021 | 367 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1559 | 0.140 |
Why?
|
Hyperglycemia | 1 | 2021 | 326 | 0.140 |
Why?
|
Inpatients | 1 | 2021 | 465 | 0.140 |
Why?
|
Healthcare Disparities | 1 | 2023 | 579 | 0.140 |
Why?
|
Clinical Chemistry Tests | 2 | 2015 | 10 | 0.140 |
Why?
|
Uracil | 1 | 2017 | 30 | 0.140 |
Why?
|
Practice Guidelines as Topic | 1 | 2025 | 1478 | 0.140 |
Why?
|
Pandemics | 2 | 2022 | 1476 | 0.140 |
Why?
|
Overweight | 2 | 2018 | 524 | 0.140 |
Why?
|
Morbidity | 1 | 2018 | 301 | 0.140 |
Why?
|
Intestines | 1 | 2020 | 344 | 0.140 |
Why?
|
Glycopeptides | 2 | 2014 | 44 | 0.140 |
Why?
|
Biological Assay | 2 | 2015 | 118 | 0.130 |
Why?
|
Smoking | 2 | 2021 | 1460 | 0.130 |
Why?
|
Vascular Patency | 1 | 2016 | 102 | 0.130 |
Why?
|
Pericarditis | 1 | 2016 | 11 | 0.130 |
Why?
|
Aortitis | 1 | 2016 | 10 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2020 | 521 | 0.130 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 5039 | 0.130 |
Why?
|
Vascular Grafting | 1 | 2016 | 12 | 0.130 |
Why?
|
Marketing | 1 | 2016 | 28 | 0.130 |
Why?
|
Uncertainty | 1 | 2016 | 114 | 0.130 |
Why?
|
Cyclopropanes | 1 | 2016 | 88 | 0.130 |
Why?
|
Telemedicine | 1 | 2024 | 782 | 0.130 |
Why?
|
Diabetic Angiopathies | 1 | 2018 | 262 | 0.130 |
Why?
|
Algorithms | 2 | 2020 | 1618 | 0.120 |
Why?
|
Piperidines | 1 | 2017 | 190 | 0.120 |
Why?
|
Multimodal Imaging | 1 | 2016 | 109 | 0.120 |
Why?
|
Down-Regulation | 1 | 2017 | 631 | 0.120 |
Why?
|
ROC Curve | 2 | 2014 | 500 | 0.120 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 269 | 0.120 |
Why?
|
Adiponectin | 1 | 2017 | 234 | 0.120 |
Why?
|
France | 3 | 2019 | 29 | 0.120 |
Why?
|
Simvastatin | 1 | 2015 | 55 | 0.120 |
Why?
|
Muscle, Skeletal | 1 | 2025 | 1627 | 0.120 |
Why?
|
Benzaldehydes | 1 | 2014 | 10 | 0.120 |
Why?
|
Oximes | 1 | 2014 | 20 | 0.120 |
Why?
|
International Cooperation | 2 | 2013 | 171 | 0.120 |
Why?
|
Decision Support Techniques | 1 | 2018 | 396 | 0.120 |
Why?
|
Mental Disorders | 1 | 2023 | 1027 | 0.110 |
Why?
|
Sleep | 1 | 2020 | 676 | 0.110 |
Why?
|
Emergency Service, Hospital | 3 | 2017 | 1901 | 0.110 |
Why?
|
Child, Preschool | 3 | 2024 | 10384 | 0.110 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 1336 | 0.110 |
Why?
|
Adolescent | 5 | 2024 | 20179 | 0.110 |
Why?
|
Hypoglycemia | 1 | 2018 | 425 | 0.110 |
Why?
|
Biomedical Research | 1 | 2020 | 635 | 0.110 |
Why?
|
Veterans | 2 | 2022 | 1398 | 0.110 |
Why?
|
Bacteria | 1 | 2020 | 808 | 0.110 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 67 | 0.110 |
Why?
|
Social Media | 1 | 2016 | 137 | 0.110 |
Why?
|
Periodicals as Topic | 1 | 2016 | 204 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2024 | 385 | 0.100 |
Why?
|
Calgranulin A | 1 | 2012 | 3 | 0.100 |
Why?
|
Calgranulin B | 1 | 2012 | 7 | 0.100 |
Why?
|
C-Reactive Protein | 2 | 2016 | 397 | 0.100 |
Why?
|
Blood Proteins | 1 | 2014 | 239 | 0.100 |
Why?
|
Gastrointestinal Microbiome | 1 | 2020 | 633 | 0.100 |
Why?
|
Internship and Residency | 1 | 2022 | 1048 | 0.100 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 37 | 0.100 |
Why?
|
Osteoprotegerin | 1 | 2012 | 25 | 0.100 |
Why?
|
Prevalence | 4 | 2019 | 2547 | 0.100 |
Why?
|
Internet | 1 | 2016 | 617 | 0.090 |
Why?
|
Neovascularization, Physiologic | 2 | 2023 | 172 | 0.090 |
Why?
|
Models, Biological | 1 | 2018 | 1691 | 0.090 |
Why?
|
Obesity, Abdominal | 1 | 2011 | 47 | 0.090 |
Why?
|
Protein Precursors | 2 | 2014 | 125 | 0.090 |
Why?
|
Femoral Artery | 2 | 2022 | 170 | 0.090 |
Why?
|
Electronic Health Records | 1 | 2018 | 974 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 872 | 0.080 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 371 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 511 | 0.080 |
Why?
|
Subclavian Steal Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
Bayes Theorem | 2 | 2023 | 369 | 0.080 |
Why?
|
Child | 3 | 2024 | 20655 | 0.080 |
Why?
|
Troponin C | 1 | 2008 | 5 | 0.080 |
Why?
|
Natriuretic Peptides | 1 | 2008 | 9 | 0.080 |
Why?
|
Multivariate Analysis | 1 | 2012 | 1484 | 0.080 |
Why?
|
Exercise Test | 2 | 2025 | 613 | 0.070 |
Why?
|
Platelet Function Tests | 2 | 2018 | 25 | 0.070 |
Why?
|
Chronic Disease | 2 | 2024 | 1705 | 0.070 |
Why?
|
Endothelial Cells | 2 | 2023 | 698 | 0.070 |
Why?
|
Death | 2 | 2020 | 121 | 0.070 |
Why?
|
Body Weight | 2 | 2023 | 928 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2012 | 518 | 0.060 |
Why?
|
Pregnancy | 2 | 2024 | 6357 | 0.060 |
Why?
|
Body Mass Index | 3 | 2023 | 2261 | 0.060 |
Why?
|
Heart Ventricles | 1 | 2010 | 765 | 0.060 |
Why?
|
Phosphocreatine | 1 | 2025 | 40 | 0.060 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 568 | 0.060 |
Why?
|
Thrombophilia | 1 | 2025 | 66 | 0.060 |
Why?
|
Gangrene | 1 | 2024 | 10 | 0.060 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2025 | 84 | 0.060 |
Why?
|
Patient Discharge | 1 | 2010 | 853 | 0.060 |
Why?
|
Coronary Stenosis | 1 | 2024 | 39 | 0.060 |
Why?
|
Everolimus | 1 | 2023 | 58 | 0.050 |
Why?
|
Plaque, Atherosclerotic | 1 | 2024 | 54 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2022 | 3328 | 0.050 |
Why?
|
Absorbable Implants | 1 | 2023 | 35 | 0.050 |
Why?
|
Inhibins | 1 | 2023 | 45 | 0.050 |
Why?
|
Soluble Guanylyl Cyclase | 1 | 2022 | 15 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2025 | 508 | 0.050 |
Why?
|
Necrosis | 1 | 2023 | 229 | 0.050 |
Why?
|
Multimorbidity | 1 | 2022 | 46 | 0.050 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2022 | 66 | 0.050 |
Why?
|
Animals | 5 | 2023 | 34479 | 0.050 |
Why?
|
Therapeutics | 1 | 2022 | 12 | 0.050 |
Why?
|
Mice | 3 | 2023 | 16602 | 0.050 |
Why?
|
Sex Factors | 2 | 2021 | 1945 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2025 | 518 | 0.050 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 711 | 0.050 |
Why?
|
Disease Progression | 2 | 2019 | 2602 | 0.050 |
Why?
|
Tissue Scaffolds | 1 | 2023 | 199 | 0.050 |
Why?
|
Coated Materials, Biocompatible | 1 | 2021 | 56 | 0.050 |
Why?
|
Sodium | 1 | 2022 | 205 | 0.050 |
Why?
|
RNA, Small Interfering | 1 | 2023 | 571 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2021 | 108 | 0.040 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 445 | 0.040 |
Why?
|
Genotyping Techniques | 1 | 2020 | 72 | 0.040 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2024 | 364 | 0.040 |
Why?
|
Drug Labeling | 1 | 2019 | 41 | 0.040 |
Why?
|
Infant | 2 | 2024 | 8914 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 680 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 500 | 0.040 |
Why?
|
Research Support as Topic | 1 | 2020 | 111 | 0.040 |
Why?
|
Aorta | 1 | 2021 | 404 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 71 | 0.040 |
Why?
|
Cardiotoxicity | 1 | 2018 | 33 | 0.040 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 57 | 0.040 |
Why?
|
Republic of Korea | 1 | 2018 | 28 | 0.040 |
Why?
|
Hip Fractures | 1 | 2019 | 82 | 0.040 |
Why?
|
Retinal Diseases | 1 | 2019 | 86 | 0.040 |
Why?
|
Spinal Fractures | 1 | 2019 | 81 | 0.040 |
Why?
|
Diet, Reducing | 1 | 2019 | 86 | 0.040 |
Why?
|
NF-kappa B | 1 | 2022 | 649 | 0.040 |
Why?
|
New Zealand | 1 | 2018 | 45 | 0.040 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 46 | 0.040 |
Why?
|
Advisory Committees | 1 | 2020 | 218 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 9 | 0.040 |
Why?
|
Sweden | 1 | 2018 | 92 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 123 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 89 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2018 | 41 | 0.040 |
Why?
|
Remission Induction | 1 | 2018 | 268 | 0.040 |
Why?
|
Machine Learning | 1 | 2022 | 445 | 0.040 |
Why?
|
Logistic Models | 1 | 2022 | 1974 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 199 | 0.040 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2017 | 6 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2023 | 703 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 331 | 0.030 |
Why?
|
England | 1 | 2017 | 73 | 0.030 |
Why?
|
Up-Regulation | 1 | 2020 | 825 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 209 | 0.030 |
Why?
|
Florida | 1 | 2017 | 93 | 0.030 |
Why?
|
Primary Prevention | 1 | 2018 | 185 | 0.030 |
Why?
|
Insulin | 2 | 2018 | 2315 | 0.030 |
Why?
|
Glucose | 1 | 2022 | 982 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2024 | 2710 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 186 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2021 | 717 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2023 | 895 | 0.030 |
Why?
|
Marfan Syndrome | 1 | 2016 | 40 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 318 | 0.030 |
Why?
|
Health Promotion | 1 | 2022 | 716 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2017 | 125 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2017 | 172 | 0.030 |
Why?
|
Bone Density | 1 | 2019 | 474 | 0.030 |
Why?
|
Curriculum | 1 | 2022 | 917 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 2264 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 245 | 0.030 |
Why?
|
Treatment Failure | 1 | 2016 | 339 | 0.030 |
Why?
|
Clinical Competence | 1 | 2022 | 1013 | 0.030 |
Why?
|
Long-Term Care | 1 | 2015 | 89 | 0.030 |
Why?
|
Mortality | 1 | 2017 | 307 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2017 | 327 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 815 | 0.030 |
Why?
|
Vaccination | 1 | 2023 | 1346 | 0.030 |
Why?
|
Publishing | 1 | 2016 | 140 | 0.030 |
Why?
|
Transcription Factors | 1 | 2022 | 1628 | 0.030 |
Why?
|
Odds Ratio | 1 | 2017 | 1023 | 0.030 |
Why?
|
Metformin | 1 | 2018 | 312 | 0.030 |
Why?
|
Sodium Channel Blockers | 1 | 2014 | 23 | 0.030 |
Why?
|
Atrial Natriuretic Factor | 1 | 2014 | 56 | 0.030 |
Why?
|
Fractures, Bone | 1 | 2019 | 418 | 0.030 |
Why?
|
Fatty Acid Binding Protein 3 | 1 | 2013 | 5 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 199 | 0.030 |
Why?
|
Limit of Detection | 1 | 2013 | 55 | 0.030 |
Why?
|
Massachusetts | 1 | 2014 | 158 | 0.030 |
Why?
|
Aortic Valve | 1 | 2016 | 345 | 0.030 |
Why?
|
Placenta Growth Factor | 1 | 2012 | 24 | 0.030 |
Why?
|
Norway | 1 | 2012 | 42 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 69 | 0.020 |
Why?
|
Creatinine | 1 | 2014 | 475 | 0.020 |
Why?
|
Interleukin-1 Receptor-Like 1 Protein | 1 | 2011 | 26 | 0.020 |
Why?
|
Blood Pressure | 1 | 2019 | 1728 | 0.020 |
Why?
|
Waist Circumference | 1 | 2011 | 138 | 0.020 |
Why?
|
Anthropometry | 1 | 2011 | 204 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2022 | 5687 | 0.020 |
Why?
|
Signal Transduction | 1 | 2023 | 4826 | 0.020 |
Why?
|
Creatine Kinase, MB Form | 1 | 2009 | 4 | 0.020 |
Why?
|
Atherectomy | 1 | 2008 | 36 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1745 | 0.020 |
Why?
|
Hemodynamics | 1 | 2011 | 1081 | 0.020 |
Why?
|
Preoperative Care | 1 | 2008 | 338 | 0.020 |
Why?
|
Research Design | 1 | 2009 | 1036 | 0.010 |
Why?
|